Pulmonary Embolism

Clinical Trial Finder

Many patients with pulmonary embolism are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Safety and Efficacy Study for Implantation and Retrieval Procedures Using the VENATECH® Retrieval Filter System

Condition:   Pulmonary Thrombo-embolism
Intervention:   Device: VenaTech® (VenaTech Retrievable Filter)
Sponsor:   B.Braun Médical - CoE Chasseneuil
Recruiting - verified February 2016

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Condition:   Venous Thromboembolism
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Conditions:   Deep Vein Thrombosis;   Malignant Neoplasm;   Portal Vein Thrombosis;   Pulmonary Embolism;   Renal Vein Thrombosis;   Venous Thromboembolism
Interventions:   Drug: Apixaban;   Drug: Dalteparin;   Other: Questionnaire Administration
Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified February 2016

Safety and Efficacy Study of Apixaban to Prevent Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With PEG Asparaginase

Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2015

Rituximab and Belimumab for Lupus Nephritis

Condition:   Lupus Nephritis
Interventions:   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Belimumab
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
Recruiting - verified February 2016

CT for Pulmonary Thromboembolic Disease

Condition:   Pulmonary Embolism
Intervention:  
Sponsor:   University of Maryland
Not yet recruiting - verified February 2016

Pulmonary Embolism Diagnosis: Ultrasound Wells Score vs Traditional Wells Score

Condition:   Pulmonary Embolism
Intervention:  
Sponsor:   Azienda Ospedaliero-Universitaria Careggi
Completed - verified February 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis.

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2016

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified February 2016

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:   Drug: Observational
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Conditions:   Chronic Obstructive Pulmonary Disease;   Patients Hospitalized for a COPD Exacerbation
Intervention:   Other: PEP
Sponsor:   University Hospital, Brest
Recruiting - verified February 2016

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Conditions:   Rivaroxaban;   Cancer-associated Thrombosis;   Recurrence;   Bleeding
Intervention:   Drug: Rivaroxaban
Sponsors:   Seoul National University Hospital;   Korean Society of Hematology Thrombosis Working Party
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT

Condition:   Deep Vein Thrombosis
Interventions:   Drug: Bemiparin sodium;   Drug: Enoxaparin sodium
Sponsor:   Berlin-Chemie AG Menarini Group
Completed - verified February 2016

Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)

Conditions:   Prophylaxis, Thromboembolism, Venous;   Total Knee Replacement;   Total Hip Replacement
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Withdrawn - verified February 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Autologous Cell Therapy After Stroke

Condition:   Stroke
Interventions:   Biological: autologous bone marrow mononuclear cell transfusion;   Biological: marrow stromal cells;   Drug: placebo
Sponsors:   University of California, Irvine;   University of California, San Diego
Withdrawn - verified February 2016

Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults

Condition:   HIV
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2016